MedPath

Effect of probiotic in patients with Multiple Sclerosis

Phase 3
Conditions
Multiple Sclerosis.
Multiple sclerosis
Registration Number
IRCT20181210041918N2
Lead Sponsor
Ahvaz University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
50
Inclusion Criteria

Selection based on revised Mc Donald criteria
a relapsing–remitting course
one or more documented relapses in the previous year or two or more in the previous 2 years
a score of 0 to 5.5 on the EDSS
Age range between 18 to 55

Exclusion Criteria

Unwillingness to continue cooperation
Exacerbation of the disease during the study
There is a relapse during the intervention
History of antibiotic use during 1 month ago
Consumption of any probiotic and prebiotic supplement and antibiotic in the last 1 month
Consumption supplements containing of vitamin, fiber, omega-3, anti-oxidants during 3 weeks before and during the study.
Taking non-steroidal anti-inflammatory drugs (NSAIDs), estrogen, progesterone, immunosuppressions, diuretics and corticosteroids drugs.
History of gastroenteritis during the last month
History of intestinal surgery during the past month
Inflammatory bowel disease (IBD), rheumatoid arthritis, systemic lupus, type 1 diabetes and other autoimmune diseases and pregnancy

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath